期刊文献+

吉西他滨联合卡培他滨治疗晚期三阴乳腺癌的临床研究 被引量:3

Clinical Researches on the Effects of Gemcitabine Combined with Capecitabine for Advanced Triple-Negative Breast Cancer Treatment
暂未订购
导出
摘要 目的探讨吉西他滨联合卡培他滨治疗晚期三阴乳腺癌(TNBC)的临床疗效及毒性反应情况。方法 40例TNBC患者给予吉西他滨联合卡培他滨治疗方案,吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1g/m2口服,2次/d,d1~d14。以上治疗方案3w为1个周期。化疗前给予地塞米松、格拉司琼止吐,化疗4个周期后评价临床疗效及毒性反应。结果本组完全缓解(CR)2例,部分缓解(PR)16例,稳定(SD)14例,进展(PD)8例,总有效率(RR)为45.0%。所有患者均随访至2012年12月,失访3例,中位肿瘤进展时间(TTP)为6.1个月。主要毒性反应包括骨髓抑制、手足综合征,次要毒性反应包括腹泻、恶心、呕吐、口腔炎、发热和脱发。结论吉西他滨联合卡培他滨治疗TNBC近期效果满意,毒性反应可耐受。 Objective To investigate the clinical effects and occurrence of toxic reactions of gemcitabine combined with capecitabine in the treatment of advanced triple-negative breast cancer (TNBC). Methods Forty patients with TNBC were treated with gemcitabine combined with capecitabine. Intravenous injection of 1 g/m2 gemcitabine was given on dl and dS,whereas 1 g/mz capecitabine was taken orally from dl to dl4,twice a day. The therapeutic regimen above lasted for 3 weeks was considered as one course of treatment. Dexamethasone and granisetron were given to stop vomiting before chemotherapy. After 4 cycles of chemotherapy,the clinical effects and toxic reactions were evaluated. Results In this group,there were 2 cases of complete remission (CR), 16 cases of partial remission (PR), 14 cases of stable disease (SD), 8 cases of progression of disease (PD), and the total remission rate (RR) was 45.0%. All patients except 3 patients were given follow-up visit till December, 2012. Their tumor medial time to progression (TTP) was 6.1 months. The primary toxic reactions included myelosuppression and hand-foot syndrome, and secondary ones included diarrhea, nausea, vomiting, stomatitis, fever and alopecia. Conclusion The short-term therapeutic effect of gemcitabine combined with capecitabine in the treatment of TNBC is satisfactory,and toxic reactions can be tolerated.
作者 郭维新
出处 《成都医学院学报》 CAS 2013年第3期324-326,共3页 Journal of Chengdu Medical College
基金 中国高校医学期刊临床专项资金项目(NO:11320124)
关键词 吉西他滨 卡培他滨 三阴乳腺癌 临床疗效 毒性反应 Gemcitabine Capecitabine Triple negative breast cancer Clinical effect Toxic reactions
  • 相关文献

参考文献12

  • 1Chu IM, Lai WC, Aprelikova O, et al. Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGF[J]. PLoS one, 2013,8 (4) :e61125.
  • 2Stevens KN, Vachon CM, Coueh FJ. Genetic susceptibility to triple4negative breast cancer [J]. Cancer Res, 2013,73 (7) : 2025-2030.
  • 3Spina A,Sapio L, Esposito A, et al. Inorganic Phosphate as a Novel Signaling Molecule with Antiproliferative Action in MDA-MB-231 Breast Cancer Cells[J] Biores Open Access, 2013,2(1) :47-54.
  • 4Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oneoiytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases[J]. Proe Natl Acad Sci USA, 2013,110(14) : E1291-E1300.
  • 5Koh M,Lee JC, Min C,et al. A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple- negative breast cancer cells[J]. Bioorg Med Chem, 2013,21 (8) :2305-2313.
  • 6Singel SM, Cornelius C, Batten K, et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple- negative breast cancer[J]. Clin Cancer Res,2013,19(8):2061- 2070.
  • 7Yu G, Liu G, Dong J, et al. Clinical implications of CIP2A protein expression in breast cancer[J]. Med Oncol, 2013,30 (2) :524.
  • 8Albain KS, Nag SM, Calderillo-Ruiz G, et a l. Gemcitabine plus Paclitaxel versus PaelitaxeI monotherapy in patients with metastatic breast cancer and prior anthracycline treatment[J]. J Clin Oncol,2008,26(24) :3950-3957.
  • 9Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer[J]. J Clin Oncol,2009,27(11) :1753-1760.
  • 10Gelmon K, Dent R, Mackey JR, et al. Targeting triple-negative breast cancer: optimising therapeutic outcomes [J]. Ann Oncol,2012,23(9) :2223-2234.

同被引文献22

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部